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   1	  
Abstract	  23	  
The	   objective	   of	   this	   study	   was	   to	   examine	   the	   use	   of	   transdermal	   iontophoresis	   for	   the	   delivery	   of	  24	  
ranitidine	  hydrochloride	  in	  children.	  Constant,	  direct	  current,	  anodal	  iontophoresis	  of	  ranitidine	  was	  performed	  in	  25	  
vitro	  across	  dermatomed	  pig	  skin.	  The	  effect	  of	  donor	  vehicle,	  current	  intensity,	  and	  drug	  concentration	  were	  first	  26	  
examined	  using	  aqueous	  solutions.	  It	  was	  found	  that	  drug	  delivery	  was	  higher	  at	  pH	  7	  (donor:	  5	  mM	  Tris)	  than	  pH	  27	  
5.6	   (donor:	   water).	   In	   the	   presence	   of	   low	   levels	   of	   competing	   background	   electrolyte,	   ranitidine	   delivery	  28	  
increased	  linearly	  with	  applied	  current	  but	  was	  independent	  of	  the	  donor	  drug	  concentration.	  The	  second	  part	  of	  29	  
the	  study	  evaluated	  two	  Pluronic®	  F-­‐127	  gels	  as	  potential	  vehicles	  for	  ranitidine	  delivery.	  The	  formulations	  were	  30	  
characterised	  in	  terms	  of	  apparent	  viscosity,	  conductivity	  and	  passive	  permeation	  measurements.	  Iontophoretic	  31	  
delivery	   of	   ranitidine	   was	   only	   slightly	   affected	   when	   delivered	   from	   the	   gels	   relative	   to	   aqueous	   solutions.	  32	  
Overall	  the	  results	  demonstrated	  that	  therapeutic	  paediatric	  doses	  of	  ranitidine	  (neonates:	  0.09-­‐0.17	  µmol/kg.h;	  33	  
1	  month	  to	  12	  years:	  0.36-­‐0.71	  µmol/kg.h)	  could	  be	  easily	  achieved	  by	  transdermal	  iontophoresis	  with	  simple	  gel	  34	  
patches	  of	  practical	  surface	  area	  (0.2-­‐1.5	  cm2/kg).	  35	  
	  36	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   2	  
1. Introduction	  40	  
Ranitidine	  is	  used	  extensively	  in	  paediatric	  medicine	  especially	  in	  intensive	  care.	  It	  is	  prescribed	  in	  a	  variety	  41	  
of	  clinical	  indications	  for	  which	  gastric	  acid	  reduction	  is	  necessary	  (British	  National	  Formulary	  for	  Children).	  This	  42	  
includes	   gastro-­‐oesophageal	   reflux	   disease,	   benign	   gastric	   and	   duodenal	   ulcerations,	   prophylaxis	   of	   acid	  43	  
aspiration	  prior	  to	  surgery,	  and	  treatment	  as	  well	  as	  prophylaxis	  from	  stress-­‐induced	  gastrointestinal	  ulcers	  and	  44	  
consequent	   haemorrhage.	   Methods	   of	   administration	   include	   oral	   and	   intravenous	   delivery.	   The	   oral	  45	  
bioavailability	  of	  ranitidine	  is	  highly	  variable	  between	  paediatric	  subjects	  especially	  in	  neonates	  (40-­‐80%	  (Garg	  et	  46	  
al.,	  1983;	  Blumer	  et	  al.,	  1985;	  Vanhecken	  et	  al.,	  1982)).	  This	  is	  due	  to	  incomplete	  absorption	  of	  the	  drug	  from	  the	  47	  
gastro-­‐intestinal	  tract	  as	  well	  as	  first-­‐pass	  metabolism.	  The	  need	  for	  frequent	  dosing	  (2	  to	  4	  times	  a	  day),	  due	  to	  48	  
the	  short	  half-­‐life	  of	  the	  drug	  (2-­‐3	  hours	  (Blumer	  et	  al.,	  1985;	  Lugo	  et	  al.,	  2001)),	  and	  the	  bitter	  taste	  of	  the	  oral	  49	  
solution,	   reduce	   child	   compliance.	   In	   addition,	   some	   formulations	   contain	   up	   to	   8%	   alcohol	   and	   no	   oral	  50	  
preparation	  is	   licensed	  for	  use	   in	  children	  under	  3	  years	  of	  age;	  parenteral	  delivery	   is	  only	   licensed	  for	  children	  51	  
over	  6	  months	  old	   (British	  National	  Formulary	   for	  Children)	  and	  has	   inherent	  pitfalls	   such	  as	  pain	  and	  distress,	  52	  
invasiveness,	  risk	  of	  infection,	  and	  technical	  difficulty.	  53	  
The	  transdermal	  route	  can	  provide	  an	  alternative	  approach	  for	  the	  delivery	  of	  ranitidine.	  The	  relatively	  non-­‐54	  
invasive	   nature	   of	   this	   administration	   method	   renders	   the	   application	   particularly	   attractive	   in	   paediatric	  55	  
medicine.	   Iontophoresis	   is	   an	   interesting	   option	   because	   it	   is	   possible	   to	   control	   delivery	   rates	   over	   extended	  56	  
periods	   of	   time.	   The	   technique	   involves	   passing	   a	   small	   electrical	   current	   (≤	   0.5	  mA/cm2)	   through	   conductive	  57	  
vehicles	   in	   contact	  with	   the	   skin.	  As	   a	   result,	   ions	  migrate	   through	   the	   skin	   towards	   the	  electrode	  of	  opposite	  58	  
charge	  (Phipps	  and	  Gyory,	  1992).	  In	  addition,	  electroosmosis	  is	  induced	  due	  to	  the	  negative	  charge	  of	  the	  skin	  at	  59	  
physiological	  pH	   (Burnette	  and	  Ongpipattanakul,	   1987;	   Luzardo-­‐Alvarez	  et	   al.,	   1998;	  Kim	  et	  al.,	   1993),	   and	   this	  60	  
facilitates	   the	   transport	   of	   neutral	   and	   positively-­‐charged	   molecules	   across	   the	   skin	   in	   the	   anode-­‐to-­‐cathode	  61	  
direction.	  Ranitidine	  hydrochloride	  is	  a	  potential	  candidate	  for	  iontophoresis.	  Target	  rates	  for	  therapeutic	  delivery	  62	  
(i.e.,	   the	  recommended	   intravenous	   infusion	  rates	  currently	  used	   in	  clinical	  care	  (British	  National	  Formulary	  for	  63	  
Children))	  are	  0.09-­‐0.17	  µmol/kg.h	  in	  neonates,	  and	  0.36-­‐0.71	  µmol/kg.h	  in	  children	  from	  1	  month	  to	  12	  years.	  	  64	  
Ranitidine	   (free	  base)	  has	  a	  molecular	  weight	  of	  314.4	  Da,	   is	   freely	  soluble	   in	  water,	  and	  has	  an	  octanol-­‐65	  
water	  partition	  coefficient	  close	  to	  2	  (log	  P	  ~0.3)	  (Moffat	  et	  al.	  2001).	  Ranitidine	  has	  two	  basic	  groups	  with	  pKa	  66	  
values	  of	  2.3	  and	  8.2	  (Brittain,	  2007)	  and	  therefore	  exists	  primarily	  as	  a	  monovalent	  cation	  between	  pH	  4	  and	  7.	  67	  
Anodal	  iontophoresis	  of	  ranitidine	  within	  this	  pH	  range	  is	  therefore	  anticipated	  to	  be	  efficient,	  predominantly	  due	  68	  
to	  electromigration	  and	  supplemented	  with	  a	  smaller	  electroosmotic	  contribution.	  	  69	  
In	   vitro	   investigations	  of	   transdermal	   iontophoresis	   are	   typically	   performed	  using	   solution-­‐based	   vehicles	  70	  
because	   of	   easy	   preparation	   and	   manipulation.	   However,	   transdermal	   systems	   for	   clinical	   applications	   are	  71	  
invariably	  semi-­‐solid	  or	  polymeric	  formulations,	  such	  as	  hydrogels.	  	  The	  latter	  are	  attractive	  because	  they	  provide	  72	  
sufficient	   rigidity	   to	  adhere	  well	   to	   the	  skin	   (without	   leakage)	  and	   their	  high	  water	  content	  provides	  a	   suitable	  73	  
conductive	  medium	   for	   iontophoresis.	   	  Nonetheless,	   it	   is	   important	   to	   test	   the	   in	   vitro	   delivery	  of	   the	  drug	  of	  74	  
interest	  from	  such	  preparations	  and	  to	  mimic	  in	  vivo	  use	  as	  closely	  as	  possible.	  Because	  non-­‐liquid	  vehicles	  may	  75	  
retard	  drug	  transport,	   it	   is	  crucial	   to	  ensure	  that	  any	  formulation	  effects	  are	  resolved	  before	  development	  of	  a	  76	  
final	  product.	  	  77	  
Pluronic®	   F-­‐127	   is	   a	   surface	  active	   gel-­‐forming	  agent	   frequently	  used	   in	   topical	   skin	   applications	   (Collett,	  78	  
2006;	  Escobar-­‐Chavez	  et	  al.,	  2006).	  It	  is	  composed	  of	  triblocks	  of	  polyoxyethylene-­‐polyoxypropylene	  copolymers	  79	  
at	   a	   ratio	   of	   70%	   ethylene	   oxide	   (hydrophilic)	   and	   30%	   propylene	   oxide	   (hydrophobic),	   and	   with	   an	   average	  80	  
molecular	  weight	  between	  9840	  and	  14600	  Da	   (Collett,	   2006;	  Booth	  and	  Attwood,	  2000;	  Cabana	  et	  al.,	   1997).	  81	  
With	   increasing	   F-­‐127	   concentration,	   or	   at	   higher	   temperatures,	   the	   entanglement	   of	   the	   polymer	   chains	  82	  
increases	  and	  the	  gel	  becomes	  more	  rigid.	   	  Pluronics®	  are	   favoured	   for	   transdermal	   iontophoresis	  because:	   (a)	  83	  
The	  non-­‐ionic	  nature	  of	  the	  surfactant	  avoids	  competition	  with	  the	  drug	  to	  carry	  the	  applied	  current,	  and	  reduces	  84	  
potential	  interaction	  between	  the	  polymer	  and	  the	  active	  (Taveira	  et	  al.,	  2009;	  Fang	  et	  al.,	  2002;	  Al-­‐Khalili	  et	  al.,	  85	  
2003;	  Gupta	  et	  al.,	  1994).	  (b)	  F-­‐127	  is	  safe	  as	  shown	  by	  its	  wide	  use	  in	  pharmaceutical	  preparations	  intended	  for	  86	  
	  	   3	  
different	   routes	   of	   administration	   (Collett,	   2006).	   (c)	   The	   thermo-­‐reversible	   properties	   of	   the	   polymer	   are	  87	  
advantageous.	  At	  15-­‐30%	  w/w	  concentrations	  in	  water,	  F-­‐127	  exists	  in	  the	  liquid	  state	  at	  low	  temperature	  (≤	  5°C)	  88	  
but	  forms	  a	  semi-­‐solid	  gel	  upon	  warming	  (>	  15°C).	  These	  unique	  rheological	  properties	  facilitate	  easy	  fabrication	  89	  
and	   straightforward	   incorporation	   with	   the	   iontophoretic	   electrodes;	   they	   also	   enable	   firm	   application	  90	  
conforming	  to	  the	  skin	  contours	  and	  preventing	  material	  from	  running	  across	  the	  skin.	  91	  
The	   purpose	   of	   this	   study	   was	   to	   investigate	   the	   potential	   of	   transdermal	   iontophoresis	   as	   a	   ranitidine	  92	  
delivery	  system	  for	  paediatric	  use.	  The	  rate	  of	  input	  of	  the	  drug	  when	  administered	  as	  a	  continuous	  intravenous	  93	  
infusion	  was	  used	  as	  a	  guide	  to	  determine	  the	  target	  transdermal	   flux	  necessary	  to	  achieve	  similar	   therapeutic	  94	  
levels.	   In	   vitro	   experiments	  were	   conducted	   to	   examine	   the	   effects	   of	   donor	   vehicle,	   drug	   concentration,	   and	  95	  
current	   intensity	   on	   the	   iontophoretic	   delivery	   of	   ranitidine	   from	   aqueous	   solutions.	   The	   most	   appropriate	  96	  
conditions	  were	  adopted	  in	  gelled	  formulations	  and	  their	  performance	  as	  potential	  delivery	  systems	  for	  ranitidine	  97	  
was	  evaluated.	  98	  
	  99	  
100	  
	  	   4	  
2. Materials	  and	  methods	  101	  
2.1 Chemicals	  	  102	  
Ranitidine	   hydrochloride,	   silver	   (Ag)	   wire	   (99.99%),	   silver	   chloride	   (AgCl,	   99.999%),	   and	   Pluronic®	   F-­‐127	  103	  
were	  purchased	   from	  Sigma	  Aldrich	   (Gillingham,	  UK).	  Tris	  base	   (α,	  α,	  α-­‐Tris-­‐(hydroxymethyl)-­‐methylamine)	  and	  104	  
sodium	   chloride	  were	   obtained	   from	   Acros	   (Geel,	   Belgium).	   Acetonitrile,	   hydrochloric	   acid	   (HCl),	   glacial	   acetic	  105	  
acid,	   and	   triethylamine	   were	   provided	   by	   Fisher	   Scientific	   (Loughborough,	   UK).	   All	   reagents	   were	   at	   least	  106	  
analytical	   grade	  and	  highly	  purified	  deionised	  water	   (resistivity	  ≥	  18.2	  MΩ.cm,	  Barnsted	  Nanopure	  DiamondTM,	  107	  
Dubuque,	  IA)	  was	  used	  for	  the	  preparation	  of	  all	  solutions.	  108	  
2.2 Skin	  109	  
Fresh	  pig	  skin	  was	  obtained	  from	  a	  local	  slaughterhouse,	  cleaned	  under	  cold	  running	  water,	  and	  stored	  in	  110	  
the	   fridge	   until	   the	   following	   day.	   Abdominal	   skin	  was	   cut	   into	   ~	   20	   x	   10	   cm2	   pieces,	   dermatomed	   (Zimmer™	  111	  
Electric	  Dermatome,	  Dover,	  Ohio.	  Nominal	  thickness	  750	  µm),	  wrapped	  individually	  in	  Parafilm™,	  and	  then	  kept	  112	  
in	  the	  freezer	  (-­‐20°C)	  until	  use.	   Immediately	  prior	  to	  the	  permeation	  experiment,	  the	  skin	  was	  thawed	  at	  room	  113	  
temperature	  for	  a	  period	  of	  30	  minutes	  and	  excess	  hair	  was	  carefully	  cut	  away	  with	  scissors.	  The	  skin	  was	  then	  114	  
mounted	  onto	  the	  diffusion	  cells	  without	  any	  further	  treatment.	  115	  
2.3 Iontophoresis	  set-­‐up	  116	  
Side-­‐by-­‐side	  two-­‐compartment	  diffusion	  cells	  (active	  transport	  area	  =	  0.78	  cm2,	  volume	  =	  3	  ml)	  were	  utilised	  117	  
in	  all	  experiments.	  The	  skin	  was	  mounted	  between	  the	  two	  chambers	  with	  the	  epidermal	  side	  oriented	  towards	  118	  
the	  anode	  compartment.	  The	  receptor	  chamber	  always	  held	  154	  mM	  sodium	  chloride	  solution	  (unbuffered,	  pH	  119	  
~6)	  and	  was	  magnetically	  stirred	  (Multipoint-­‐6	  stirrer,	  Thermo	  Scientific	  Variomag,	  Cole-­‐Parmer,	  London,	  UK)	  at	  120	  
400	  rpm	  throughout	  the	  experiment.	  Anodal,	  direct,	  constant	  current	  was	  delivered	  using	  Ag/AgCl	  electrodes	  and	  121	  
a	   power	   supply	   (KEPCO	   1000M,	   Flushing,	   NY,	   USA).	   Hourly	   samples	   (0.5	   ml)	   of	   the	   receptor	   phase	   were	  122	  
withdrawn	  and	  replaced	  with	  fresh	  solution.	  Separate	  passive	  diffusion,	  control	  experiments	  were	  also	  performed	  123	  
with	   samples	   taken	   every	   2	   hours	   for	   10	   hours	   and	   two	   final	   samples	  withdrawn	   at	   22	   and	   24	   h.	   Again	   each	  124	  
sample	  taken	  was	  replaced	  with	  0.5	  ml	  fresh	  solution.	  125	  
2.3.1 Ranitidine	  delivery	  from	  aqueous	  solutions	  126	  
Prior	  to	  the	  start	  of	  the	  transport	  study,	  the	  skin	  was	  left	  for	  30	  minutes	  in	  contact	  with	  the	  donor	  vehicle	  127	  
without	  drug,	  and	  154	  mM	  sodium	  chloride	   in	  the	  receptor	  chamber.	  Both	  compartments	  were	  then	  refreshed	  128	  
with	  new	  donor	   (now	  containing	   ranitidine)	  and	  receptor	  solutions.	  Experiments	  examined	  donor	  vehicle,	  drug	  129	  
concentration,	   and	   current	   intensity	   effects	   on	   the	   iontophoretic	   delivery	   of	   ranitidine.	   Specific	   conditions	  130	  
examined	  are	  summarised	  in	  Table	  1.	  	  131	  
2.3.2 Ranitidine	  delivery	  from	  gel	  formulations	  132	  
Two	  gel	  formulations	  were	  prepared	  according	  to	  the	  “cold	  method”	  (Schmolka,	  1996).	  Solutions	  containing	  133	  
150	  mM	  ranitidine	  in	  5	  mM	  Tris	  (pH	  7)	  were	  cooled	  to	  ~3-­‐5°C	  under	  continuous	  gentle	  agitation.	  F-­‐127	  (at	  20	  and	  134	  
30%	  w/w)	  was	  then	  incorporated	  slowly	  into	  the	  solutions	  and	  the	  resulting	  formulations	  were	  stirred	  for	  2	  days	  135	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Table	  1:	  	   Experimental	  conditions	  performed	  to	  characterise	  ranitidine	  transdermal	  delivery	  from	  aqueous	  140	  
solutions.	  141	  













5mM	  Tris	   7*	   5	  
Current	  	   5mM	  Tris	   50	   7*	  
0.1	   5	  
0.2	   4	  
0.3	   5	  
Concentration	  	   5mM	  Tris	  
25	  
7*	   0.3	  
5	  
50	   5	  
150	   5	  
Passive	  diffusion	   5mM	  Tris	   150	   7*	   0	   3	  
*	  pH	  adjusted	  to	  7	  with	  1M	  HCl.	  	  142	  
**	  number	  of	  replicates	  143	  
For	  the	  permeation	  experiments,	  3.3	  grams	  of	  each	  formulation	  was	  added	  to	  the	  donor	  compartment	  and	  144	  
constant	   current	   (0.3	   mA)	   was	   delivered	   for	   6	   hours.	   The	   voltage	   across	   each	   iontophoresis	   system	   was	  145	  
monitored	  regularly.	  All	  experiments	  were	  conducted	  at	  22.2	  ±	  0.9°C,	  and	  both	  compartments	  were	  covered	  with	  146	  
Parafilm	  to	  avoid	  water	  evaporation.	  	  147	  
2.4 Viscosity	  measurements	  148	  
The	   apparent	   viscosities	   of	   the	   gel	   formulations	   were	   determined	   using	   a	   Bohlin	   rheometer	   (Malvern	  149	  
Instruments,	  Malvern,	  UK)	  equipped	  with	  a	  cone-­‐plate	  system.	  The	  angle	  of	  the	  cone	  was	  4°	  and	  the	  diameter	  of	  150	  
the	  plate	  was	  40	  mm.	  Three	  specific	  shear	  rates	  were	  tested	  (0.1,	  1,	  or	  10	  1/s)	  with	  a	  gap	  size	  set	  at	  150	  mm.	  151	  
Readings	  were	  performed	  at	  22.1	  ±	  0.2°C	  and	  gels	  were	  allowed	  to	  equilibrate	  on	  the	  plate	  for	  5	  minutes	  before	  152	  
the	  measurements	  were	  made.	  The	  viscosities	  of	  control	  formulations	  (without	  ranitidine)	  were	  also	  verified	  and	  153	  
all	  measurements	  were	  performed	  in	  triplicate.	  154	  
2.5 Conductivity	  measurements	  155	  
The	  conductivities	  of	  the	  gel	  formulations	  were	  measured	  (T-­‐120	  conductivity	  meter,	  Metrohm	  AG,	  Herisau,	  156	  
Switzerland;	   cell	   reference	   =	   0.85)	   at	   22°C.	   These	  were	   compared	   to	   the	   conductivity	   of	   ranitidine	   in	   aqueous	  157	  
solution.	  All	  measurements	  were	  performed	  in	  triplicate.	  158	  
2.6 Sample	  analysis	  159	  
Quantification	  of	  ranitidine	  was	  performed	  by	  high	  performance	  liquid	  chromatography	  with	  UV	  detection	  160	  
(315	  nm).	  The	  method	  was	  modified	  from	  a	  previous	  publication	  (Oo	  et	  al.,	  1995)	  and	  used	  a	  Jasco	  HPLC	  system	  161	  
comprising:	  a	  PU-­‐980	  pump	  with	  an	  AS-­‐1595	  autosampler,	  a	  UV-­‐975	  UV-­‐VIS	  detector,	  and	  a	  HiQ-­‐SilTM	  C18	  (250	  x	  162	  
4.6	  mm,	  5µm)	  reverse-­‐phase	  column	  (Jasco	  UK,	  Ltd.,	  Dunmow,	  UK)	  thermostatted	  at	  25°C.	  The	  mobile	  phase	  (pH	  163	  
3.8)	   consisted	   of	   a	  mixture	   of	  water,	   acetonitrile,	   acetic	   acid,	   and	   triethylamine	   (85:15:1.5:0.2,	   respectively	   in	  164	  
volume),	  and	  was	  pumped	  through	  the	  system	  at	  1	  ml/min.	  	  165	  
2.7 Data	  analysis	  and	  statistics	  166	  
Data	  analysis	  and	  regressions	  were	  performed	  using	  Graph	  Pad	  Prism	  V.5.00	  (Graph	  Pad	  Software	  Inc.,	  La	  167	  
Jolla,	  CA,	  USA).	  Unless	  otherwise	  stated,	  data	  are	  represented	  as	  the	  mean	  ±	  standard	  deviation	  (SD).	  Transport	  168	  
fluxes	  were	  calculated	  as	  the	  amounts	  delivered	  during	  a	  permeation	  period	  divided	  by	  the	  length	  of	  that	  period.	  169	  
	  	   6	  
Statistical	  significance	  was	  set	  at	  p	  <	  0.05.	  Comparisons	  made	  between	  different	  sets	  of	  data	  were	  assessed	  by	  170	  
either	  a	  two-­‐tailed	  unpaired	  t-­‐test	  (for	  2	  groups)	  or	  a	  one-­‐way	  ANOVA	  (for	  >2	  groups)	  followed	  by	  Tukey’s	  post-­‐171	  
test.	  Comparison	  of	  ranitidine	  transdermal	  delivery	  from	  gel	  formulations	  relative	  to	  aqueous	  solution	  was	  made	  172	  
with	  a	  two-­‐way	  ANOVA	  followed	  by	  Bonferroni	  post-­‐tests.	  173	  
The	  transference	  number	  (T)	  of	  ranitidine	  was	  computed	  according	  to	  Faraday’s	  law	  [6]:	  T	  =	  {(JtotalzF)/I},	  174	  
where	  Jtotal	  is	  the	  total	  flux	  observed	  at	  6	  h,	  (I)	  is	  the	  current	  intensity	  applied,	  (F)	  is	  Faraday’s	  constant,	  and	  z	  the	  175	  
absolute	  value	  of	  the	  valence	  of	  the	  drug	  ion	  (~1).	  176	  
	  177	  
178	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3. Results	  and	  discussion	  179	  
3.1 Ranitidine	  delivery	  from	  aqueous	  solutions	  180	  
The	  donor	  concentrations	  of	  ranitidine	  hydrochloride	  (25-­‐150	  mM)	  provided	  sufficient	  chloride	  ions	  for	  the	  181	  
Ag/AgCl	   electrochemistry	   at	   the	   anode.	   The	   passive	   diffusion	   flux	   of	   ranitidine	   from	   the	   highest	   donor	  182	  
concentration	  used	  (150	  mM)	  was	  only	  0.1	  ±	  0.04	  nmol/h	  after	  6	  hours	  diffusion	  and	  was	  negligible	  relative	  to	  183	  
that	  achieved	  with	  iontophoresis.	  	  184	  
3.1.1 Effect	  of	  donor	  vehicle	  185	  
The	  first	  iontophoresis	  experiments	  used	  a	  donor	  solution	  containing	  only	  ranitidine	  hydrochloride	  (25	  mM)	  186	  
in	  water.	   The	  pH	  of	   this	   unbuffered	   solution	  was	   around	  5.6	   and	  was	   low	  enough	   to	   ensure	   almost	   complete	  187	  
ionisation	   (93%)	  of	   the	  more	  basic	   group	  of	   ranitidine	   (pKa	   8.2).	   Ranitidine	  was	   the	  only	   cation	  present	   in	   the	  188	  
donor	  compartment,	  therefore,	  resulting	  in	  the	  maximum	  iontophoretic	  transport	  possible	  with	  the	  flux	  reaching	  189	  
0.61	  ±	  0.08	  µmol/h	  after	  6	  hours	  of	  current	  passage	  (Figure	  1);	  this	  corresponds	  to	  a	  transference	  number	  of	  5.47	  190	  









Figure	   1:	  Ranitidine	   iontophoretic	   transport	   (mean	  ±	   SD;	   applied	   current	   =	   0.3	  mA)	   as	   a	   function	  of	   time	   from	  200	  
donor	  solutions	  containing	  25	  mM	  drug	  at	  pH	  5.6	  (in	  water)	  and	  7	  (in	  5	  mM	  Tris	  buffer).	  	  201	  
	  202	  
The	  next	  donor	  vehicle	  examined	  contained	  5	  mM	  Tris	  buffer	  with	  the	  final	  pH	  adjusted	  to	  7	  with	  1	  M	  HCl.	  	  203	  
The	   iontophoretic	   fluxes	  were	   initially	   similar	   to	   those	  measured	   at	   pH	   5.6,	   but	   attained	   a	   value	   (0.78	   ±	   0.07	  204	  
µmol/h),	  after	  6	  hours	  of	  current	  passage,	  which	  was	  significantly	  higher	  (p	  <	  0.05)	  (Figure	  2),	  and	  corresponded	  205	  
to	   a	   transference	   number	   of	   6.95	   (±	   0.58)%.	   	   Thus,	   even	   though	   the	   presence	   of	   Tris	   introduced	   co-­‐ion	  206	  
competition	  with	   ranitidine	   (~4.6	  mM	  of	   positively	   charged	   Tris	   at	   pH	   7,	   pKa	   8.1),	   the	   higher	   pH	  of	   the	   donor	  207	  
solution	   enhanced	   the	   overall	   electrotransport	   of	   the	   drug	   (presumably	   a	   combination	   of	   a	   greater	   negative	  208	  
charge	  on	  the	  skin	  (pI~4.5	  (Marro	  et	  al.,	  2001)	  and	  an	  enhanced	  electroosmotic	  flow)	  (Phipps	  and	  Gyory,	  1992;	  209	  
Marro	  et	  al.,	  2001;	  Santi	  and	  Guy,	  1996).	  This	   result	   is	  consistent	  with	  previous	  observations	   for	  other	  cations,	  210	  
including	  sodium	  (Sieg	  et	  al.,	  2004),	  verapamil	  (Wearley	  et	  al.,	  1989),	  and	  sumatriptan	  (Patel	  et	  al.,	  2007).	  211	  
3.1.2 Effect	  of	  current	  intensity	  212	  
These	  experiments	  were	  designed	  (a)	  to	  confirm	  that	  iontophoresis	  provides	  a	  controllable	  means	  to	  deliver	  213	  
ranitidine,	  and	  (b)	  to	  determine	  whether	  acceptably	  small	  current	  intensities	  can	  are	  able	  to	  provide	  therapeutic	  214	  
drug	  doses.	  While	  a	   current	  density	  of	  up	   to	  0.5	  mA/cm2	   is	   considered	   tolerable	  by	  adult	   subjects,	   it	   is	   clearly	  215	  
desirable	  to	  use	  lower	  levels	  in	  children,	  and	  especially	  neonates,	  to	  reduce	  discomfort	  and	  improve	  compliance.	  216	  
Three	   current	   intensities	  were	   examined:	   0.1,	   0.2,	   and	   0.3	  mA,	   (0.13,	   0.26,	   and	   0.39	  mA/cm2)	   at	   a	   fixed	   drug	  217	  































Figure	  2:	  Iontophoretic	  delivery	  of	  ranitidine	  (mean	  ±	  SD)	  from	  a	  50	  mM	  donor	  solution	  (containing	  5	  mM	  Tris,	  pH	  226	  
7)	  as	  a	  function	  of	  time	  (left)	  and	  current	  intensity	  (right),	  with	  which	  the	  flux	  at	  6	  hr	  was	  highly	  correlated	  (r2	  =	  227	  
0.97,	  p	  <	  0.0001).	  	  	  228	  
As	  expected,	  and	  in	  agreement	  with	  Faraday’s	  law	  and	  several	  earlier	  publications	  (e.g.,	  Green	  et	  al.,	  1992;	  229	  
Padmanabhan	   et	   al.,	   1990;	   van	   der	   Geest	   et	   al.,	   1997;	   Singh	   et	   al.,	   1999)),	   the	   current	   intensity	   directly	  230	  
determined	  the	  permeation	  of	  ranitidine	  across	  the	  skin	  (Figure	  2).	  The	  drug’s	  transference	  number,	  calculated	  231	  
from	   the	   slope	  of	   the	   linear	   dependence	  of	   flux	   at	   6	   hr	   against	   current	   intensity,	  was	   7.05	   (±	   0.33)%;	   in	   good	  232	  
agreement	  with	  that	  determined	  in	  the	  first	  series	  of	  experiments	  using	  half	  the	  ranitidine	  concentration	  in	  the	  233	  
donor.	  	  234	  
At	   the	   lowest	   current	   density	   used	   (0.13	   mA/cm2),	   the	   delivery	   rate	   of	   ranitidine	   was	   0.31	   (±0.02)	  235	  
µmol/h.cm2.	   This	   flux	   is	   sufficient	   to	   satisfy	   the	   recommended	   intravenous	   infusion	   dose	   of	   ranitidine	   for	  236	  
neonates	   (0.09-­‐0.17	   µmol/kg.h),	   and	   for	   children	   older	   than	   1	   month	   (0.36-­‐0.71	   µmol/kg.h)	   (British	   National	  237	  
Formulary	  for	  Children,	  2008),	  with	  patch	  application	  areas	  (anode	  +	  cathode)	  of	  only	  0.6-­‐1.1	  cm2/kg	  for	  neonates	  238	  
and	   2.3-­‐4.6	   cm2/kg	   for	   older	   children.	   Obviously,	   with	   increasing	   current	   density,	   the	   area	   required	   is	  239	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Figure	   3:	   Estimated	   patch	   areas	   required	   to	   achieve	   therapeutic	   input	   rates	   of	   ranitidine,	   as	   a	   function	   of	   the	  249	  
iontophoretic	   current	   density	   applied.	   4	   age	  groups	   are	   used	   to	   illustrate	   The	   range	  of	   areas	   necessary	   in	   four	  250	  
illustrative	  paediatric	  populations	  are	  shown.	  251	  
3.1.3 Effect	  of	  drug	  concentration	  252	  
The	  delivery	  of	  ranitidine	  as	  a	  function	  of	  donor	  concentration	  is	  shown	  in	  Figure	  4.	  	  No	  significant	  impact	  253	  
was	  observed	  and	  the	  flux	  only	  increased	  from	  0.78	  (±0.07)	  to	  0.90	  (±0.10)	  	  µmol/h	  despite	  a	  six-­‐fold	  increase	  in	  254	  
drug	  concentration	  in	  the	  donor.	  	  This	  is	  because	  the	  molar	  fractions	  of	  drug	  used	  in	  the	  three	  experiments	  are	  255	  
not	  that	  different	  (being	  0.84,	  0.91	  and	  0.97	  for	  25,	  50	  and	  150	  mM	  drug,	  respectively).	  	  256	  






















































1 year old (10 kg)

























Figure	  4:	  Ranitidine	  flux	  (mean	  ±	  SD)	  after	  6	  h	  of	   iontophoresis	  as	  a	  function	  of	  donor	  concentration	  and	  molar	  265	  
fraction.	  	  266	  
3.2 Ranitidine	  delivery	  from	  gel	  formulations	  267	  
Pluronic®	  F-­‐127	  (at	  20	  or	  30%	  w/w)	  as	  used	  to	  produce	  gel	  formulations	  containing	  ranitidine	  at	  150	  mM	  in	  268	  
5	  mM	  Tris	   buffer	   (pH	  7).	   	   The	   current	   intensity	   employed	  was	  0.3	  mA.	   The	  highest	   concentration	  of	   drug	  was	  269	  
chosen	  to	  counteract,	  as	  much	  as	  possible,	  any	  potential	  effects	  that	  gelation	  of	  the	  vehicle	  might	  have	  on	  the	  270	  
electrotransport	  of	  ranitidine.	  	  271	  
3.2.1 Apparent	  viscosity	  measurements	  272	  
Figure	   5	   displays	   the	   apparent	   viscosity	   of	   each	   gel	   formulation	  with	   and	  without	   ranitidine.	   The	   values	  273	  
were	   unaffected	   by	   the	   presence	   of	   the	   drug,	   implying	   that	   it	   did	   not	   interfere	   with	   the	  274	  
micellisation/entanglement/packing	  of	  the	  F-­‐127.	  	  The	  formulations	  were	  semi-­‐solid	  at	  22°C	  but	  the	  viscosity	  of	  275	  
that	  containing	  30%	  w/w	  polymer	  was	  significantly	  greater	  than	  that	  with	  less	  (e.g.,	  at	  an	  applied	  shear	  rate	  of	  0.1	  276	  
s-­‐1,	  the	  apparent	  viscosity	  of	  the	  20%	  w/w	  F-­‐127	  was	  863	  (±67)	  Pa.s,	  while	  that	  with	  30%	  w/w	  polymer	  was	  5139	  277	  
(±302)	   Pa.s).	   The	   20%	   gel	   structure	   was	   “soft”	   relative	   to	   the	   more	   rigid	   semi-­‐solid	   consistency	   of	   the	   30%	  278	  
formulation,	   which	   would	   be	   more	   appropriate	   for	   transdermal	   applications.	   The	   flow	   curves	   of	   the	   gel	  279	  
formulations	  conformed	  (with	  r2	  values	  of	  ≥0.98)	  to	  the	  Ostwald-­‐De	  Waele	  power	   law	  (Macosko,	  1994;	  Malkin,	  280	  
1994;	  Goodwin	  and	  Hughes,	  2008):	  η	  =	  Kγn-­‐1,	  where	  η	   is	  the	  apparent	  viscosity	  measured	  at	  a	  particular	  shear	  281	  









Figure	  5:	  Apparent	  viscosities	  of	  F-­‐127	  gels	  measured	  at	  different	  shear	  rates.	  	  Regression	  of	  the	  data	  yielded	  the	  291	  
following	  parameters	  from	  the	  power	  law	  relation:	  (a)	  for	  the	  20%	  w/w	  gel,	  K	  and	  n	  were,	  respectively,	  119	  (±1)	  292	  
and	   0.14	   (±0.01)	   with	   drug,	   and	   91	   (±5)	   and	   0.11	   (±0.03)	   without;	   (b)	   for	   the	   30%	   w/w	   gel,	   K	   and	   n	   were,	  293	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   10	  
The	   n	   index	   values	   of	   all	   formulations	   were	   below	   1	   indicating	   pseudoplastic	   behaviour;	   further,	   the	  295	  
inverse	   relationship	  between	   the	   apparent	   viscosity	   and	   the	   applied	   shear	   rate	   shows	   that	   the	   gels	   are	   shear-­‐296	  
thinning	  fluids.	  Even	  at	  high	  shear	  rates,	  the	  apparent	  viscosity	  of	  the	  gels	  remained	  in	  the	  linear	  regime	  of	  the	  297	  
power	  law	  suggesting	  that	  the	  internal	  network	  structure	  of	  the	  formulations	  was	  stable.	  	  298	  
3.2.2 Conductivity	  measurements	  	  299	  
The	  conductivity	  of	  the	  high	  concentration	  drug	  formulation	  without	  gelation	  was	  7.9	  (±0.1)	  mSi/cm;	  with	  300	  
20	  and	  30%	  w/w	  F-­‐127,	  the	  conductivities	  were	  significantly	  less	  (4.3	  (±0.03)	  and	  2.9	  (±0.02)	  mSi/cm,	  respectively)	  301	  
and	   significantly	   different	   from	   one	   another.	   In	   accordance	   with	   Stoke’s	   law	   (Kuhn	   et	   al.,	   2008),	   these	  302	  
observations	  suggest	  that	  ion	  mobility	  (and	  hence	  conductivity)	  and	  formulation	  viscosity	  are	  inversely	  related.	  303	  
3.2.3 Voltage	  measurements	  304	  
The	   voltage	   across	   the	   diffusion	   cells	   was	   monitored	   throughout	   the	   iontophoresis	   experiments	   at	   an	  305	  
applied	  current	  of	  0.3	  mA	  and	  the	  average	  results	  (±SD)	  are	  shown	  in	  Figure	  6.	   	  The	  voltage	  was	  highest	  at	  the	  306	  
start	  of	  iontophoresis	  because	  skin	  resistance	  is	  greatest	  at	  this	  point;	  it	  then	  fell	  off	  as	  ions	  were	  driven	  into	  the	  307	  
membrane,	  which	  became	  progressively	  more	  conductive.	   	   	   It	   is	  apparent,	   furthermore,	   that	   the	  nature	  of	   the	  308	  
donor	  formulation	  also	  contributed	  to	  the	  total	  resistance	  of	  the	  iontophoretic	  circuit,	  and	  that	  this	  contribution	  309	  
increased	  with	   the	   viscosity	   of	   the	   gels	   used	   (being	   higher	   for	   the	   30%	  w/w	  polymer	   than	   the	   one	   containing	  310	  
20%).	   	   However,	   the	   2-­‐fold	   increase	   observed	   would	   be	   of	   trivial	   significance	   in	   terms	   of	   the	   feasibility	   and	  311	  








Figure	   6:	   Average	   voltage	   applied	   (mean	   ±	   SD)	   across	   the	   diffusion	   cells	   as	   a	   function	   of	   time	   of	   current	  320	  
application	  (0.3	  mA)	  for	  an	  aqueous	  donor	  solution	  (0%)	  and	  for	  the	  two	  F-­‐127	  gels	  examined	  (20%	  and	  30%).	  321	  
	  322	  
3.2.4 Permeation	  studies	  323	  
Figure	  7	  (left	  panel)	  shows	  the	  passive	  diffusion	  profiles	  of	  ranitidine	  from	  donor	  formulations	  containing	  0	  324	  
(control),	  20	  and	  30%	  w/w	  of	   the	  gelling	  agent	  F-­‐127.	  After	  24	  hours,	   cumulative	  amounts	  of	  18.6	   (±6.9),	  15.6	  325	  
(±4.7),	  and	  9.2	  (±4.6)	  nmol/cm2,	  respectively,	  had	  permeated	  through	  the	  skin.	  	  At	  most,	  therefore,	  these	  values	  326	  
suggest	   that	   the	   gelling	   agent	   at	   its	   highest	   concentration	   only	   leads	   to	   a	   50%	   reduction	   in	   the	   passive	   skin	  327	  
permeation	  rate.	  From	  a	  practical	  standpoint,	  this	  effect	  is	  of	  little	  consequence,	  given	  the	  much	  greater	  delivery	  328	  
rates	  achieved	  with	  iontophoresis,	  as	  shown	  in	  Figure	  7	  (right	  panel).	  	  329	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  330	  
Figure	   7:	   Passive	   diffusion	   (left	   panel)	   and	   iontophoretic	   delivery	   (right	   panel)	   of	   ranitidine	   from	   an	   aqueous	  331	  
solution	  and	  from	  two	  F-­‐127	  gel	  formulations	  and	  liquid	  solution.	  Data	  are	  expressed	  as	  mean	  ±	  SD.	  332	  
The	   electrotransport	   of	   ranitidine	   after	   6	   hr	   of	   current	   passage	   was	   0.90	   (±0.10)	   μmol/h	   from	   aqueous	  333	  
solution,	  and	  0.95	  (±0.10)	  and	  0.75	  (±0.07)	  µmol/h,	  respectively	  from	  the	  20%	  and	  30%	  w/w	  F-­‐127	  gels.	  Two-­‐way	  334	  
ANOVA	   tests	   on	   the	   fluxes	   from	   the	   4th	   hour	   of	   iontophoresis	   indicated	   that	   delivery	   from	   the	   30%	   polymer	  335	  
formulation	   was	   significantly	   lower,	   albeit	   by	   only	   ~20%	   (i.e.,	   a	   difference	   of	   little	   practical	   importance).	   The	  336	  
calculated	  transference	  numbers	  of	  ranitidine	  from	  the	  control,	  and	  from	  the	  20	  and	  30%	  w/w	  F-­‐127	  formulations	  337	  
were	  8.05	  (±0.91),	  8.48	  (±0.87),	  and	  6.73	  (±0.63)%,	  respectively.	  	  338	  
Assuming	   that	   the	   flux	   rates	   achieved	  with	   the	   gel	   formulations	   are	   achievable	   in	   vivo,	   the	   patch	   areas	  339	  
required	  to	  achieve	  therapeutic	   input	   levels	  of	  ranitidine	  were	  estimated	  and	  are	  summarised	   in	  Table	  2.	  From	  340	  
these	   results,	   it	   would	   appear	   that	   the	   F-­‐127	   gel	   formulations	   may	   be	   able	   to	   iontophoretically	   deliver	  341	  
therapeutically	  effective	  fluxes	  from	  acceptable	  patch	  application	  areas.	  342	  
4. Conclusions	  343	  
Transdermal	  iontophoresis	  of	  ranitidine	  enhanced	  its	  delivery	  significantly	  relative	  to	  the	  passive	  diffusion.	  344	  
The	  manipulation	  of	  different	  parameters	  allowed	  the	  drug’s	  iontophoretic	  delivery	  to	  be	  optimised	  so	  that	  target	  345	  
therapeutic	   levels	   with	   both	   solution	   and	   gel	   formulations	  might	   be	   attained.	   In	   particular,	   a	   gel	   formulation	  346	  
comprising	  30%	  w/w	  F-­‐127	  polymer	  showed	  promise,	  having	  an	  appropriate	  viscosity	  for	  transdermal	  application,	  347	  
an	  acceptable	  electrical	  conductivity,	  and	  achieving	  the	  desired	  iontophoretic	  efficiency.	  	  	  Specifically,	  the	  results	  348	  
obtained	  suggest	  that	  therapeutic	   levels	  of	  ranitidine	   in	  children	  up	  to	  the	  age	  of	  12	  years	  might	  be	  achievable	  349	  
with	  a	  total	  patch	  area	  of	  only	  0.2-­‐1.5	  cm2/kg.	  350	  
	  351	  
Table	  2:	  Calculated	  iontophoresis	  gel	  patch	  sizes	  necessary	  to	  achieve	  target	  systemic	  levels	  of	  ranitidine	  in	  352	  
different	  paediatric	  populations.	  	  353	  
	  354	  
	  
Target	  input	  rate	  
(µmol/h.kg)(1)	  
In	  vitro	  transdermal	  rates	  
achieved(2)	  (µmol/h.cm2)	  
Total	  area	  of	  patch	  
required	  (cm2/kg)	  
Neonate	   0.09	  –	  0.17	   Solution:	  1.16	  (±0.13)	  
	  
Gel	  20%:	  1.22	  (±0.13)	  
	  
Gel	  30%:	  0.97	  (±0.09)	  
0.1	  –	  0.3	  
0.1	  –	  0.3	  
0.2	  –	  0.4	  
1	  month	  –	  
12	  years	  
0.36	  –	  0.71 
0.6	  –	  1.2	  
0.6	  –	  1.2	  
0.7	  –	  1.5 
(1):	  Typical	  intravenous	  infusion	  rates.	  	  355	  
(2):	  Fluxes	  achieved	  after	  6	  hour	  iontophoresis	  (at	  a	  current	  density	  of	  0.39	  mA/cm2,	  and	  a	  donor	  formulation	  containing	  150	  356	  
mM	  drug	  (pH	  7)).	  	  357	  
358	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